WO2001046200A8 - Novel piperidine and piperazine derivatives - Google Patents

Novel piperidine and piperazine derivatives

Info

Publication number
WO2001046200A8
WO2001046200A8 PCT/SE2000/002580 SE0002580W WO0146200A8 WO 2001046200 A8 WO2001046200 A8 WO 2001046200A8 SE 0002580 W SE0002580 W SE 0002580W WO 0146200 A8 WO0146200 A8 WO 0146200A8
Authority
WO
WIPO (PCT)
Prior art keywords
piperazine derivatives
novel piperidine
piperidine
pharmaceutical compositions
novel
Prior art date
Application number
PCT/SE2000/002580
Other languages
French (fr)
Other versions
WO2001046200A1 (en
Inventor
Premji Meghani
Colin Bennion
Original Assignee
Astrazeneca Ab
Premji Meghani
Colin Bennion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP00989102A priority Critical patent/EP1242427B1/en
Priority to IL15020100A priority patent/IL150201A0/en
Application filed by Astrazeneca Ab, Premji Meghani, Colin Bennion filed Critical Astrazeneca Ab
Priority to US10/168,094 priority patent/US6969713B2/en
Priority to JP2001547110A priority patent/JP2003518126A/en
Priority to AT00989102T priority patent/ATE247123T1/en
Priority to CA002394095A priority patent/CA2394095A1/en
Priority to BR0016543-3A priority patent/BR0016543A/en
Priority to NZ519498A priority patent/NZ519498A/en
Priority to MXPA02006261A priority patent/MXPA02006261A/en
Priority to DE60004564T priority patent/DE60004564T2/en
Priority to AU25648/01A priority patent/AU776592B2/en
Publication of WO2001046200A1 publication Critical patent/WO2001046200A1/en
Publication of WO2001046200A8 publication Critical patent/WO2001046200A8/en
Priority to IL150201A priority patent/IL150201A/en
Priority to NO20023037A priority patent/NO20023037L/en
Priority to US11/125,335 priority patent/US20050272745A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/04—1,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

The invention provides piperidine and piperazine derivatives of general formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.
PCT/SE2000/002580 1999-12-22 2000-12-18 Novel piperidine and piperazine derivatives WO2001046200A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
MXPA02006261A MXPA02006261A (en) 1999-12-22 2000-12-18 Novel piperidine and piperazine derivatives.
NZ519498A NZ519498A (en) 1999-12-22 2000-12-18 Novel piperidine and piperazine derivatives
US10/168,094 US6969713B2 (en) 1999-12-22 2000-12-18 Piperidine and piperazine acetamide derivatives
IL15020100A IL150201A0 (en) 1999-12-22 2000-12-18 Novel piperidine and piperazine derivatives
AT00989102T ATE247123T1 (en) 1999-12-22 2000-12-18 NEW PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS
CA002394095A CA2394095A1 (en) 1999-12-22 2000-12-18 Novel piperidine and piperazine derivatives
DE60004564T DE60004564T2 (en) 1999-12-22 2000-12-18 NEW PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS
EP00989102A EP1242427B1 (en) 1999-12-22 2000-12-18 Novel piperidine and piperazine derivatives as p2x7 receptor antagonists
JP2001547110A JP2003518126A (en) 1999-12-22 2000-12-18 New piperidine and piperazine derivatives
BR0016543-3A BR0016543A (en) 1999-12-22 2000-12-18 New piperidine and piperazine derivatives
AU25648/01A AU776592B2 (en) 1999-12-22 2000-12-18 Novel piperidine and piperazine derivatives
IL150201A IL150201A (en) 1999-12-22 2002-06-12 Piperidine and piperazine derivatives, process for their production, pharmaceutical compositions comprising them and use thereof in therapy
NO20023037A NO20023037L (en) 1999-12-22 2002-06-21 New piperidine and piperazine derivatives
US11/125,335 US20050272745A1 (en) 1999-12-22 2005-05-10 Novel piperidine and piperazine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904738A SE9904738D0 (en) 1999-12-22 1999-12-22 Novel compounds
SE9904738-3 1999-12-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/125,335 Continuation US20050272745A1 (en) 1999-12-22 2005-05-10 Novel piperidine and piperazine derivatives

Publications (2)

Publication Number Publication Date
WO2001046200A1 WO2001046200A1 (en) 2001-06-28
WO2001046200A8 true WO2001046200A8 (en) 2002-02-28

Family

ID=20418266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2000/002580 WO2001046200A1 (en) 1999-12-22 2000-12-18 Novel piperidine and piperazine derivatives

Country Status (17)

Country Link
US (2) US6969713B2 (en)
EP (1) EP1242427B1 (en)
JP (1) JP2003518126A (en)
KR (1) KR100733548B1 (en)
CN (1) CN1330657C (en)
AT (1) ATE247123T1 (en)
AU (1) AU776592B2 (en)
BR (1) BR0016543A (en)
CA (1) CA2394095A1 (en)
DE (1) DE60004564T2 (en)
IL (2) IL150201A0 (en)
MX (1) MXPA02006261A (en)
NO (1) NO20023037L (en)
NZ (1) NZ519498A (en)
SE (1) SE9904738D0 (en)
WO (1) WO2001046200A1 (en)
ZA (1) ZA200204307B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904505D0 (en) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
WO2003013571A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7115741B2 (en) * 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (en) 2001-11-12 2003-06-30 Pfizer Prod Inc BENZAMIDA, HETEROARILAMIDA AND INVESTED AMIDAS
WO2003082855A1 (en) * 2002-03-28 2003-10-09 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
PA8591801A1 (en) 2002-12-31 2004-07-26 Pfizer Prod Inc BENZAMID INHIBITORS OF THE P2X7 RECEIVER.
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
DE602004005033T2 (en) * 2003-05-12 2007-08-09 Pfizer Products Inc., Groton BENZAMIDINHIBITORS OF THE P2X7 RECEPTOR
GB0324498D0 (en) 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
WO2005107804A1 (en) * 2004-05-06 2005-11-17 Ono Pharmaceutical Co., Ltd. Therapeutic agent for respiratory ailment
JP2008504360A (en) * 2004-06-29 2008-02-14 ファイザー・プロダクツ・インク 5- [4- (2-hydroxy-propyl) -3,5-dioxo-4,5-dihydro-3H-1,2,4-triazin-2-yl by deprotecting the hydroxyl protected precursor Method for producing benzamide derivative
CA2572119A1 (en) * 2004-06-29 2006-01-12 Warner-Lambert Company Llc Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
JP2008505100A (en) * 2004-06-30 2008-02-21 シェーリング　コーポレイション Substituted N-arylsulfonyl heterocyclic amines as gamma-secretase inhibitors
CA2594987A1 (en) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. Therapeutic agent for constipation
US8153803B2 (en) 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
US20080021063A1 (en) * 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
GB0713602D0 (en) * 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
EP2212300A1 (en) 2007-10-26 2010-08-04 Glaxo Group Limited 4-benz0yl-1-substituted-piperazin-2-0ne derivatives as p2x7 modulators
US8232290B2 (en) 2008-03-25 2012-07-31 Affectis Pharmaceuticals Ag P2X7R antagonists and their use
PT2243772E (en) 2009-04-14 2012-03-28 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CA2771592A1 (en) * 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Substituted heterocyclic derivatives for the treatment of pain and epilepsy
EP2322149A1 (en) 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia
BR112012028850A2 (en) 2010-05-14 2015-09-15 Affectis Pharmaceuticals Ag methods for preparing p2x7r antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
GB201114212D0 (en) 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
AR090037A1 (en) 2011-11-15 2014-10-15 Xention Ltd DERIVATIVES OF TIENO AND / OR FURO-PYRIMIDINES AND PYRIDINES INHIBITORS OF THE POTASSIUM CHANNELS
TW201427947A (en) * 2012-10-12 2014-07-16 Lundbeck & Co As H Cyclic amines
WO2014134306A1 (en) 2013-03-01 2014-09-04 Zalicus Pharmaceuticals, Ltd. Heterocyclic inhibitors of the sodium channel
SI3180334T1 (en) * 2014-08-16 2019-01-31 Suven Life Sciences Limited Process for large scale production of n-(4-(1- cyclobutyl piperidin-4-yloxy) phenyl)-2-(morpholin-4-yl) acet amide dihydrochloride
CN107205970A (en) 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 Immunomodulator
UY36390A (en) * 2014-11-05 2016-06-01 Flexus Biosciences Inc MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3029241A (en) * 1962-04-10 Phenylpbperazinylacyl anilines
JPS5849550B2 (en) * 1974-02-07 1983-11-05 住友化学工業株式会社 Synchronous aniline usage information
FR2346011A1 (en) * 1976-02-02 1977-10-28 Orsymonde (4)-Phenyl-(1)-dimethylacetanilido-piperazine and salts - esp. for treating cardiovascular circulatory disorders
ZA825719B (en) 1981-09-03 1983-06-29 Recordati Chem Pharm Alkanoylanilides
JPH03141258A (en) * 1989-10-25 1991-06-17 Kowa Co Novel piperazine derivative
CA2101311A1 (en) * 1992-07-31 1994-02-01 Neelakantan Balasubramanian Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles
JP3229693B2 (en) * 1993-02-22 2001-11-19 協和醗酵工業株式会社 Piperazine derivative
AU2980797A (en) * 1996-06-11 1998-01-07 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
SE9704545D0 (en) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (en) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
WO1999031096A1 (en) * 1997-12-18 1999-06-24 Shaman Pharmaceuticals, Inc. Piperazine derivatives useful as hypoglycemic agents
AU3985699A (en) * 1998-05-19 1999-12-06 Centaur Pharmaceuticals, Inc. Amide therapeutics for the treatment of inflammatory bowel disease
RU2254333C2 (en) 1999-04-09 2005-06-20 Астразенека Аб Derivatives of adamantane, method for their preparing, pharmaceutical composition based on thereof and methods for treatment
SE9901875D0 (en) 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
SE9904505D0 (en) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
SE9904652D0 (en) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
AU2564801A (en) 2001-07-03
DE60004564T2 (en) 2004-06-24
NZ519498A (en) 2004-02-27
KR20020069221A (en) 2002-08-29
EP1242427A1 (en) 2002-09-25
NO20023037L (en) 2002-08-22
ZA200204307B (en) 2003-08-29
US20050272745A1 (en) 2005-12-08
IL150201A0 (en) 2002-12-01
CN1330657C (en) 2007-08-08
NO20023037D0 (en) 2002-06-21
IL150201A (en) 2008-06-05
CN1434827A (en) 2003-08-06
CA2394095A1 (en) 2001-06-28
SE9904738D0 (en) 1999-12-22
KR100733548B1 (en) 2007-06-28
ATE247123T1 (en) 2003-08-15
BR0016543A (en) 2002-09-17
DE60004564D1 (en) 2003-09-18
US20030013721A1 (en) 2003-01-16
US6969713B2 (en) 2005-11-29
JP2003518126A (en) 2003-06-03
MXPA02006261A (en) 2002-12-05
EP1242427B1 (en) 2003-08-13
WO2001046200A1 (en) 2001-06-28
AU776592B2 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
WO2001046200A8 (en) Novel piperidine and piperazine derivatives
HUP0204245A3 (en) Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use
SE9904505D0 (en) Novel compounds
HUP0203136A3 (en) Piperazine compounds, process for their preparation, pharmaceutical compositions containing them and their use
AU2001264474A1 (en) Admantane derivatives
HUP0204515A3 (en) 4-aminopiperidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203548A3 (en) New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
MY125978A (en) Admantane derivatives
HUP0203316A3 (en) Amino-triazolopyridine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0203183A3 (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
HUP0202787A3 (en) Piperazine derivatives as 5-ht1b antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0201516A3 (en) 13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0201753A2 (en) Pyridopyranoazepine derivatives, process for their preparation and pharmaceutical compositions containing them
AU2001269198A1 (en) Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them
HUP0202075A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203184A3 (en) Isoxazolecarboxamide derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0203320A3 (en) Indolylpiperidine derivatives and their use as antihistaminic and antiallergic agents, process for their preparation, pharmaceutical compositions containing them
GB0109122D0 (en) Novel compounds
HUP0202731A3 (en) O-anisamide derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0201315A3 (en) 4-phenyl-pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0201797A3 (en) 3-amino-2-benzyl-1-phenyl-propane derivatives, process for their preparation, pharmaceutical compositions containing them and their use
IL145041A0 (en) Novel morpholine derivatives, methods for the production thereof and pharmaceutical preparations containing said derivatives
HUP0203161A3 (en) Benzamidine derivatives, process for their preparation and pharmaceutical compositions containing them and their use
HUP0203650A3 (en) Heterocyclic derivatives, process for their preparation, pharmaceutical compositions containing them and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 25648/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002/04307

Country of ref document: ZA

Ref document number: 200204307

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2000989102

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2394095

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 519498

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 150201

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 10168094

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2001 547110

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/006261

Country of ref document: MX

Ref document number: 1020027008039

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 008190453

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027008039

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000989102

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2000989102

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 519498

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 519498

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 25648/01

Country of ref document: AU